Advertisement

U.S. markets closed

S&P Futures
3,957.25
+16.75(+0.43%)
Dow Futures
31,964.00
+84.00(+0.26%)
Nasdaq Futures
11,846.75
+75.75(+0.64%)
Russell 2000 Futures
1,770.60
+6.20(+0.35%)
Crude Oil
110.43
+0.66(+0.60%)
Gold
1,866.40
+1.00(+0.05%)

Advertisement

WEF 2022

Yahoo Finance is in Davos! Get the latest updates here

Fennec Pharmaceuticals Inc. (FENC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

5.58

-0.12

(-2.11%)

At close: 04:00PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

MACD

View all chart patterns

Performance Outlook

Previous Close	5.70
Open	5.60
Bid	5.51 x 1200
Ask	5.59 x 1000
Day's Range	5.26 - 5.68
52 Week Range	3.82 - 10.08
Volume	43,898
Avg. Volume	35,772

Market Cap	149.249M
Beta (5Y Monthly)	-0.07
PE Ratio (TTM)	N/A
EPS (TTM)	-0.63
Earnings Date	Aug 08, 2022 - Aug 12, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	11.20

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for FENC

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Fennec Pharmaceuticals Inc.
Weekly Stock ListESG Stocks
Rating
Fair Value
Economic Moat
2 days agoArgus Research

All

GlobeNewswire
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., May 23, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that the Company will be participating in upcoming conferences. The management team will also host one-on-one investor meetings at the conferences. Presentation Details: Even
- Citi CEO Jane Fraser to Present at Bernstein’s 38th Annual Strategic Decisions Conference
  Business Wire
- Olema Oncology to Present at Jefferies Healthcare Conference
  GlobeNewswire
GlobeNewswire
Fennec Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update
~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~ ~ If Approved by the FDA, PEDMARKTM Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ ~ Company Has Approximately $18.3 Million in Cash and $5 Million of Funded Debt ~ RESEARCH TRIANGLE PARK, N.C., May 12, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM
American City Business Journals
Inflation crushes market caps of Triangle's biggest public companies – except these ones
As inflation keeps climbing, market capitalization – and profits – are sinking at Triangle companies. And economists say it could be just the beginning.